Double labeling immunofluorescent staining for LC3B and Gal-3 showed a significantly higher number of cells expressing LC3b in the kidneys of the CIS-treated GAL-3 KO mice than in the CIS-treated Gal-3 wild mice (p < 0.001) (Figure 5). This evidence concerns the gene MAP1LC3B and in situ carcinoma.